EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy

Sumbul Khan, Theresa A Higgins, Isabella Shimko-Lofano, Maninder Sandey, Emma Logsdon, Gracie Bunch, Yasin Fatemi, Leah M K Hoffman, Bruce F Smith, Payal Agarwal

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04458-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Sumbul Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Scott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA. Hauptthemen laut MEDLINE: Osteosarcoma, Oncolytic Virotherapy, Oncolytic Viruses, Bone Neoplasms. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma (OS) is a highly aggressive bone malignancy that predominantly affects children and young adults. There have been no major changes in patient survival in the past four decades. Therefore, new therapeutic interventions are needed. We have developed an enhanced conditionally replicative canine oncolytic adenovirus, CAV2-AU-M3, armed with an anti-PD1 heavy-chain antibody (HcAb), and evaluated its efficacy against osteosarcoma across four canine cell lines. CAV2-AU-M3 was characterized for its infectivity, lytic properties, and anti-PD1 Ab production in monolayer and spheroid cultures. Additionally, the impact of intratumoral administration of the virus on tumor growth was measured in a mouse model. Our study demonstrates that CAV2-AU-M3 infects and lyses different canine OS cell lines at varying rates but produces anti-PD1 Ab at similar levels across all osteosarcoma cell lines. Additionally, anti-PD1 Ab produced by CAV2-AU-M3 can effectively bind the cell surface PD1 receptor and inhibit the binding of PDL1 to PD1 receptors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaOncolytic VirotherapyOncolytic VirusesBone NeoplasmsAdenoviruses, CanineAnimalsDogsMiceHumansCell Line, TumorProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsOncolytic VirusesOsteosarcomaTumor MicroenvironmentTumor Spheroids

Substanzen

Programmed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Scott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
  • Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
  • Department of Mathematics and Statistics, College of Sciences and Mathematics, Auburn University, Auburn, AL, USA.
  • Department of Industrial and Systems Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, AL, USA.
  • Scott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL, USA. agarwpa@auburn.edu.
  • Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA. agarwpa@auburn.edu.

Förderung

  • NCI NIH HHS
  • NIH NCI

Zitieren

APA

Khan, S., Higgins, T. A., Shimko-Lofano, I., Sandey, M., Logsdon, E., Bunch, G., Fatemi, Y., Hoffman, L. M. K., Smith, B. F., & Agarwal, P. (2026). Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04458-0

Vancouver

Khan S, Higgins TA, Shimko-Lofano I, Sandey M, Logsdon E, Bunch G, et al. Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04458-0

BibTeX
@article{Khan2026,
  author = {Khan, Sumbul and Higgins, Theresa A and Shimko-Lofano, Isabella and Sandey, Maninder and Logsdon, Emma and Bunch, Gracie and Fatemi, Yasin and Hoffman, Leah M K and Smith, Bruce F and Agarwal, Payal},
  title = {Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04458-0}
}
Kostenlos starten →